The efficacy of erythropoietin (EPO) can be enhanced by the addition of granulocyte colony‐stimulating factor (G‐CSF), mainly in MDS with ring sideroblasts; the median duration of response to the combined treatment is around 30 months, with some patients responding for more than 10 years 1. The gene discussed is EPO; the disease is myelodysplastic syndrome.